WallStSmart

Merck & Company Inc (MRK)vsDr. Reddy’s Laboratories Ltd ADR (RDY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Dr. Reddy’s Laboratories Ltd ADR generates 411% more annual revenue ($335.93B vs $65.77B). MRK leads profitability with a 13.6% profit margin vs 12.8%. RDY appears more attractively valued with a PEG of 1.61. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

RDY

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 5.5Value: 5.0Quality: 7.5
Piotroski: 2/9Altman Z: 3.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for RDY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

RDY3 strengths · Avg: 9.7/10
Free Cash FlowQuality
$10.75B10/10

Generating 10.7B in free cash flow

Altman Z-ScoreHealth
3.1810/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RDY4 concerns · Avg: 3.5/10
PEG RatioValuation
1.614/10

Expensive relative to growth rate

Price/BookValuation
16.8x4/10

Trading at 16.8x book value

Operating MarginProfitability
1.5%3/10

Operating margin of 1.5%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : RDY

The strongest argument for RDY centers on Free Cash Flow, Altman Z-Score, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : RDY

The primary concerns for RDY are PEG Ratio, Price/Book, Operating Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while RDY is a declining play — different risk/reward profiles.

RDY carries more volatility with a beta of 0.26 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

RDY generates stronger free cash flow (10.7B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 48/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Dr. Reddy’s Laboratories Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India.

Want to dig deeper into these stocks?